Understanding the tumor microenvironment in head and neck squamous cell carcinoma.

Rad, HS; Shiravand, Y; Radfar, P; Ladwa, R; Perry, C; Han, X; Warkiani, ME; Adams, MN; Hughes, BG; O'Byrne, K; Kulasinghe, A

Understanding the tumor microenvironment in head and neck squamous cell carcinoma.

Rad, HS Shiravand, Y Radfar, P Ladwa, R Perry, C Han, X Warkiani, ME Adams, MN Hughes, BG O'Byrne, K Kulasinghe, A

Permalink

Publisher:: WILEY
Publication Type:: Journal Article
Citation:: Clin Transl Immunology, 2022, 11, (6), pp. e1397
Issue Date:: 2022

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (1.56 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Rad, HS
dc.contributor.author	Shiravand, Y
dc.contributor.author	Radfar, P
dc.contributor.author	Ladwa, R
dc.contributor.author	Perry, C
dc.contributor.author	Han, X
dc.contributor.author	Warkiani, ME
dc.contributor.author	Adams, MN
dc.contributor.author	Hughes, BG
dc.contributor.author	O'Byrne, K
dc.contributor.author	Kulasinghe, A
dc.date.accessioned	2023-02-06T02:19:25Z
dc.date.available	2022-05-19
dc.date.available	2023-02-06T02:19:25Z
dc.date.issued	2022
dc.identifier.citation	Clin Transl Immunology, 2022, 11, (6), pp. e1397
dc.identifier.issn	2050-0068
dc.identifier.issn	2050-0068
dc.identifier.uri	http://hdl.handle.net/10453/165927
dc.description.abstract	Head and neck squamous cell carcinoma (HNSCC) represents a heterogeneous group of tumors. While significant progress has been made using multimodal treatment, the 5-year survival remains at 50%. Developing effective therapies, such as immunotherapy, will likely lead to better treatment of primary and metastatic disease. However, not all HNSCC tumors respond to immune checkpoint blockade therapy. Understanding the complex cellular composition and interactions of the tumor microenvironment is likely to lead to new knowledge for effective therapies and treatment resistance. In this review, we discuss HNSCC characteristics, predictive biomarkers, factors influencing immunotherapy response, with a focus on the tumor microenvironment.
dc.format	Electronic-eCollection
dc.language	eng
dc.publisher	WILEY
dc.relation.ispartof	Clin Transl Immunology
dc.relation.isbasedon	10.1002/cti2.1397
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1107 Immunology, 1115 Pharmacology and Pharmaceutical Sciences
dc.title	Understanding the tumor microenvironment in head and neck squamous cell carcinoma.
dc.type	Journal Article
utslib.citation.volume	11
utslib.location.activity	Australia
utslib.for	1107 Immunology
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
pubs.organisational-group	/University of Technology Sydney/Strength - IBMD - Initiative for Biomedical Devices
pubs.organisational-group	/University of Technology Sydney/Centre for Health Technologies (CHT)
utslib.copyright.status	open_access	*
dc.date.updated	2023-02-06T02:19:21Z
pubs.issue	6
pubs.publication-status	Published online
pubs.volume	11
utslib.citation.issue	6

Abstract:

Head and neck squamous cell carcinoma (HNSCC) represents a heterogeneous group of tumors. While significant progress has been made using multimodal treatment, the 5-year survival remains at 50%. Developing effective therapies, such as immunotherapy, will likely lead to better treatment of primary and metastatic disease. However, not all HNSCC tumors respond to immune checkpoint blockade therapy. Understanding the complex cellular composition and interactions of the tumor microenvironment is likely to lead to new knowledge for effective therapies and treatment resistance. In this review, we discuss HNSCC characteristics, predictive biomarkers, factors influencing immunotherapy response, with a focus on the tumor microenvironment.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/165927